Dr. Daniel Sullivan honored for leadership in quantitative imaging biomarkers

MEDIA CONTACT: Lisa Berry Edwards
703-519-2107
Lisa.Edwards@preventcancer.org

Alexandria, VA—The Prevent Cancer Foundation today honored Daniel C. Sullivan, M.D. with the James L. Mulshine, M.D. Leadership Award for his work in founding and chairing the Quantitative Imaging Biomarkers Alliance (QIBA). QIBA is committed to transforming patient care by making radiology a more quantitative science.

As part of the Radiological Society of North America (RSNA), QIBA is the leading international organization working to standardize the use of imaging biomarkers in research and clinical practice across 28 different imaging platforms. The goal is to develop comprehensive quality measures to reduce measurement differences between various hardware and software components used in quantitative medical imaging. Standardizing the performance steps for all professional groups involved in using imaging to measure disease progression is critical to ensuring the reliability of quantitative imaging methods in clinical decision making.  

“QIBA is a remarkable international organization working to integrate emerging advanced medical imaging into useful tools to advance care for all,” said Dr. Jim Mulshine, Scientific Director of the Prevent Cancer Foundation, for whom the award is named. “Thanks to his sustained and gracious efforts in nurturing the development of QIBA, as well as his leadership efforts in imaging development at the National Cancer Institute, Dr. Sullivan is broadly acknowledged as making extraordinary contributions to medical innovation.”

Dr. Sullivan has both clinical and research expertise in nuclear medicine and oncologic imaging, with a focus on improving the use of imaging as a biomarker in clinical trials and clinical practice.

He completed his radiology residency and nuclear medicine fellowship in 1977 at Yale New Haven Hospital. Dr. Sullivan has held faculty appointments at Yale University Medical Center, Duke University Medical Center, and University of Pennsylvania Medical Center. He joined the National Cancer Institute (NCI) at the National Institutes of Health (NIH) in 1997. At NCI, from 1997 to 2007, Dr. Sullivan served as associate director in the Division of Cancer Treatment and Diagnosis and the head of the Cancer Imaging Program (CIP).

がん予防財団について^®

がん予防財団^® is celebrating 35 years as the only U.S. nonprofit organization focused solely on saving lives across all populations through cancer prevention and early detection.  Through research, education, outreach and advocacy, we have helped countless people avoid a cancer diagnosis or detect their cancer early enough to be successfully treated.

当財団は、2035 年までにがんによる死亡者数を 40% 削減するという課題に立ち向かうべく立ち上がっています。この目標を達成するために、当財団は、がんを早期に発見し、複数のがんのスクリーニングを進めるための革新的な技術に $20 百万ドル、医療サービスが行き届いていないコミュニティへのがんスクリーニングとワクチン接種のアクセス拡大に $10 百万ドル、スクリーニングとワクチン接種の選択肢について一般の人々を啓蒙するために $10 百万ドルを投資することを約束しています。

詳細については、 がん予防.